ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Net Change in Cash
ADC Therapeutics SA
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Net Change in Cash
-$47.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Net Change in Cash
CHf46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Change in Cash
$177m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Change in Cash
-CHf44.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
8%
|
|
Idorsia Ltd
SIX:IDIA
|
Net Change in Cash
CHf44.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Change in Cash
-CHf9.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Net Change in Cash?
Net Change in Cash
-47.8m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Net Change in Cash amounts to -47.8m USD.
What is ADC Therapeutics SA's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
17%
Over the last year, the Net Change in Cash growth was 66%.